University of California, San Francisco.
Group Health Research Institute, Seattle, Washington.
JAMA. 2016 Jun 21;315(23):2564-2575. doi: 10.1001/jama.2016.5989.
Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134,000 persons will be diagnosed with the disease, and about 49,000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 68 years.
To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer.
The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screening methods.
The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States.
The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history (C recommendation).
结直肠癌是美国癌症死亡的第二大主要原因。2016 年,预计将有 13.4 万人被诊断患有该疾病,约 4.9 万人将死于该疾病。结直肠癌最常发生在 65 至 74 岁的成年人中;结直肠癌的中位死亡年龄为 68 岁。
更新 2008 年美国预防服务工作组(USPSTF)关于结直肠癌筛查的建议。
USPSTF 审查了使用结肠镜检查、软性乙状结肠镜检查、计算机断层结肠摄影术、愈创木based 粪便潜血试验、粪便免疫化学试验、多靶标粪便 DNA 试验和甲基化 SEPT9 DNA 试验筛查结直肠癌的有效性,减少发病率和死亡率以及全因死亡率;这些筛查试验的危害;以及这些试验检测腺瘤、基于大小的高级腺瘤或两者的检测性能特征,以及结直肠癌。USPSTF 还委托进行了一项比较建模研究,以提供有关不同可用筛查方法的最佳起始和停止年龄以及筛查间隔的信息。
USPSTF 得出的结论是,对 50 至 75 岁无明显症状的平均风险成年人进行结直肠癌筛查具有实质性的净收益。有多种筛查策略可供选择,这些策略的有效性证据水平不同,并且具有独特的优点和局限性,尽管没有经验数据表明任何已审查的策略都能提供更大的净收益。在美国,结直肠癌筛查是一项严重未被充分利用的预防保健策略。
USPSTF 建议从 50 岁开始筛查结直肠癌,并持续到 75 岁(A 级建议)。对于 76 至 85 岁成年人是否进行结直肠癌筛查,应根据患者的整体健康状况和既往筛查史做出个体化决定(C 级建议)。